Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 54 points (-0.3%) at 17,704 as of Thursday, July 2, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,396 issues advancing vs. 1,580 declining with 168 unchanged.

The Health Care sector currently sits down 0.7% versus the S&P 500, which is down 0.3%. Top gainers within the sector include

Vertex Pharmaceuticals

(

VRTX

), up 3.8%,

AstraZeneca

(

AZN

), up 1.0%,

Novartis

(

NVS

), up 1.0%,

Shire

(

SHPG

), up 0.8% and

Teva Pharmaceutical Industries

(

TEVA

), up 0.7%. On the negative front, top decliners within the sector include

Centene

(

CNC

), down 5.9%,

Alkermes

(

ALKS

), down 2.7%,

Anthem

(

ANTM

), down 1.6%,

Boston Scientific

(

BSX

), down 1.5% and

St Jude Medical

(

STJ

), down 1.4%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3.

Health Net

(

TheStreet Recommends

HNT

) is one of the companies pushing the Health Care sector higher today. As of noon trading, Health Net is up $7.02 (10.8%) to $72.08 on heavy volume. Thus far, 8.2 million shares of Health Net exchanged hands as compared to its average daily volume of 613,100 shares. The stock has ranged in price between $71.76-$76.67 after having opened the day at $76.67 as compared to the previous trading day's close of $65.06.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Health Net, Inc. provides managed health care services through health plans and government-sponsored managed care plans in the United States. It operates through Western Region Operations and Government Contracts segments. Health Net has a market cap of $4.9 billion and is part of the health services industry. Shares are up 21.5% year-to-date as of the close of trading on Wednesday. Currently there are 3 analysts who rate Health Net a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Health Net

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Health Net Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Eli Lilly and

(

LLY

) is up $0.42 (0.5%) to $85.27 on light volume. Thus far, 1.5 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 5.1 million shares. The stock has ranged in price between $84.69-$85.35 after having opened the day at $85.21 as compared to the previous trading day's close of $84.85.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. Eli Lilly and has a market cap of $92.7 billion and is part of the drugs industry. Shares are up 23.0% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Eli Lilly and

as a

buy

. The company's strengths can be seen in multiple areas, such as its expanding profit margins, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Eli Lilly and Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Celgene

(

CELG

) is up $1.30 (1.1%) to $119.52 on average volume. Thus far, 2.4 million shares of Celgene exchanged hands as compared to its average daily volume of 4.6 million shares. The stock has ranged in price between $118.52-$119.89 after having opened the day at $118.56 as compared to the previous trading day's close of $118.22.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. Celgene has a market cap of $91.8 billion and is part of the drugs industry. Shares are up 5.7% year-to-date as of the close of trading on Wednesday. Currently there are 13 analysts who rate Celgene a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Celgene

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and notable return on equity. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Celgene Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).